Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients

Trial Profile

Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium (68Ga) gozetotide (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 27 Jan 2024 Results (n=277; From December 2015 to December 2019) comparing the prognostic value of presurgical PSMA-PET and pelvic lymph nodes invasion (pN1) for biochemical recurrence (BCR) free-survival (FS) in patients with intermediate-risk to high-risk prostate cancer (PCa) treated with radical prostatectomy (RP) and pelvic lymph node dissection from NCT03368547, NCT02611882, NCT02919111 trials, presented at the 2024 Genitourinary Cancers Symposium.
    • 07 Jun 2022 Results of post-hoc follow-up study from (n = 764; NCT03368547, NCT02611882, NCT02919111) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 Results determining the accuracy of 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases (N1) compared to histopathology at time of radical prostatectomy (NCT03368547, NCT02611882, NCT02919111) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top